Scholar Rock Holding (SRRK) closed at $40.24 on October 19, 2026, up 0.9% from the previous close, on volume of 1,430,011 shares (30-day average 2,097,149).
Data as of October 19, 2026.
19-Oct-2026
Bank of America Securities Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)
TipRanks (Fri, 16-Oct 11:15 PM ET)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 16-Oct 4:15 PM ET)
Business Wire (Thu, 8-Oct 8:00 AM ET)
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
PRNewswire (Wed, 30-Sep 9:56 AM ET)
Business Wire (Fri, 11-Sep 6:25 PM ET)
Business Wire (Wed, 2-Sep 8:00 AM ET)
Scholar Rock to Present at Upcoming Investor Conferences
Business Wire (Thu, 27-Aug 8:00 AM ET)
Business Wire (Fri, 21-Aug 9:06 AM ET)
Business Wire (Fri, 7-Aug 4:20 PM ET)
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Business Wire (Thu, 6-Aug 7:00 AM ET)
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Scholar Rock Holding trades on the NASDAQ stock market under the symbol SRRK.
As of October 19, 2026, SRRK stock price climbed to $40.24 with 1,430,011 million shares trading.
SRRK has a beta of 1.51, meaning it tends to be more sensitive to market movements. SRRK has a correlation of 0.08 to the broad based SPY ETF.
SRRK has a market cap of $4.90 billion. This is considered a Mid Cap stock.
Last quarter Scholar Rock Holding reported $0 in Revenue and -$.84 earnings per share. This fell short of revenue expectation by $-2 million and met earnings estimates .
In the last 3 years, SRRK traded as high as $61.76 and as low as $6.48.
The top ETF exchange traded funds that SRRK belongs to (by Net Assets): VTI, IWM, XBI, VB, VXF.
SRRK has outperformed the market in the last year with a return of +36.7%, while the SPY ETF gained +17.2%. However, in the most recent history, SRRK shares have underperformed the stock market with its stock returning -22.2% in the last 3 month period and -14.0% for the last 2 week period, while SPY has returned +2.4% and -0.4%, respectively.
SRRK support price is $38.63 and resistance is $41.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRRK shares will trade within this expected range on the day.
